Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
International Journal of Cancer|April 1, 2005
Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapyChristina Ebbinghaus, Roberto Ronca, Manuela Kaspar, et al.
Protein Engineering, Design & Selection : PEDS|November 22, 2008
A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cellsKathrin Zuberbühler, Alessandro Palumbo, Camilla Bacci, et al.
Protein Engineering, Design & Selection : PEDS|June 17, 2010
Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12Roberto Sommavilla, Nadine Pasche, Eveline Trachsel, et al.
International Journal of Cancer|February 14, 2008
A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivoAlessandra Villa, Eveline Trachsel, Manuela Kaspar, et al.
Blood|November 14, 2008
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2Christoph Schliemann, Alessandro Palumbo, Kathrin Zuberbühler, et al.
Cancer Research|October 28, 2010
In vivo imaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomographyViviane Mumprecht, Michael Honer, Benjamin Vigl, et al.
Cancer Research|March 7, 2012
Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenograftsMichele Moschetta, Francesca Pretto, Alexander Berndt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2011
A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanomaThomas K Eigentler, Benjamin Weide, Filippo de Braud, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2010
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinomaManfred Johannsen, Gianluca Spitaleri, Giuseppe Curigliano, et al.
Pageof 2